Funded Startups in Solna
Among the seven most recent Solna-funded entries, the largest disclosed round is Moleculent’s $20M on 2026-04-30, and it sits among the higher disclosed am…
Among the seven most recent Solna-funded entries, the largest disclosed round is Moleculent’s $20M on 2026-04-30, and it sits among the higher disclosed amounts in the list rather than dwarfing them. The disclosed amounts cluster in a mid-to-high range ($12M for Cellcolabs on 2025-10-29, $19M for Ovzon on 2023-02-03, and $24M for Chromafora on 2024-12-20), while the two most recent rows (PDS Vision Group on 2026-02-03 and Moleculent on 2026-04-30) include one undisclosed amount.
Sector-wise, biotechnology appears repeatedly (Moleculent, Cellcolabs, Pelago Bioscience), alongside standalone coverage in Manufacturing (Chromafora), Telecommunications (lynes), Hardware (Ovzon), and Information Technology (PDS Vision Group). Temporally, these rounds are concentrated from 2023-02-03 through 2026-04-30, with three entries landing in 2023 alone (Ovzon, lynes, Pelago Bioscience). Disclosures are also mixed: 4 of 7 rows list disclosed amounts, while 3 of 7 are undisclosed.
Most recent rounds
7 shownRelated listings
Frequently asked
What’s the largest disclosed round in Solna on this page, and does it stand out versus other disclosed amounts?
Moleculent’s $20M (2026-04-30) is the single largest disclosed amount shown, and it is close to the top disclosed peers: Chromafora’s $24M (2024-12-20) and Ovzon’s $19M (2023-02-03). The remaining disclosed rounds include $12M (Cellcolabs, 2025-10-29), so the spread stays within the same general band rather than separating into a clear outlier range.
How much of the list falls into a narrow recent window (by round date)?
Within the two-year span from 2024-12-20 to 2026-04-30, there are three dated entries: Chromafora ($24M, 2024-12-20), Cellcolabs ($12M, 2025-10-29), and Moleculent ($20M, 2026-04-30). The rest of the dated rounds shown start earlier, including Pelago Bioscience (undisclosed, 2023-08-16) and Ovzon ($19M, 2023-02-03).
Are any sectors over-represented among these seven companies?
Biotechnology is the only sector that appears in 3+ entries: Moleculent (2026-04-30), Cellcolabs (2025-10-29), and Pelago Bioscience (2023-08-16) all list Biotechnology. Other sectors here are each represented once, including Manufacturing (Chromafora, 2024-12-20), Telecommunications (lynes, 2023-03-15), Hardware (Ovzon, 2023-02-03), and Information Technology (PDS Vision Group, 2026-02-03).
What does the disclosure pattern look like for deal size on these rows?
Disclosed amounts appear in 4 of 7 rows: Moleculent ($20M, 2026-04-30), Cellcolabs ($12M, 2025-10-29), Chromafora ($24M, 2024-12-20), and Ovzon ($19M, 2023-02-03). The remaining 3 of 7 rows are explicitly undisclosed: PDS Vision Group (2026-02-03), Pelago Bioscience (2023-08-16), and lynes (2023-03-15).
Is there a recent or older-date skew in the sectors shown?
Biotechnology appears across both ends of the shown time window: Moleculent (2026-04-30, $20M) and Cellcolabs (2025-10-29, $12M) are more recent, while Pelago Bioscience is also Biotechnology but older at 2023-08-16 (undisclosed). Non-biotech coverage is more dispersed across years, such as Ovzon in Hardware on 2023-02-03 ($19M) and Chromafora in Manufacturing on 2024-12-20 ($24M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.